 |
市場調查報告書
商品編碼
2112608
細胞療法製造市場（第七版）：按細胞療法類型、細胞來源、細胞技術、企業規模、製造商類型和主要地區分類－趨勢與預測至2035年Cell Therapy Manufacturing Market (7th Edition) by Type of Cell Therapy, Source of Cells, Origin of Cells, Technology, Scale of Operation, Type of Manufacturer, Key Geographical Regions - Trends and Forecast Till 2035 |
||||||
價格
細胞療法製造市場概覽
全球細胞療法製造市場預計將從今年的 72 億美元成長到 2035 年的 140 億美元，預測期內的複合年成長率約為 7.7%。
細胞療法製造市場—成長與趨勢
細胞療法正迅速成為現代醫學中最具臨床創新性的治療方法之一。目前，全球有超過1000種細胞和基因療法候選藥物正在積極研發中，近45種細胞療法已獲得全球監管機構的批准。隨著該療法從個人化介入發展成為可規模化生產的治療手段，研發人員越來越依賴專業的生產合作夥伴來擴大細胞療法的生產規模。
該行業正在經歷一場決定性的轉變，向封閉式、自動化和標準化的製造平台轉型，旨在減少人工干預，提高批次間的一致性，並支持規模化生產模式。
此外，受藥品進口關稅風險的驅動，美國正在加速投資國內先進治療藥物生產基礎設施，而印度和沙烏地阿拉伯等新興經濟體也在建立本地生產能力，以支持價格合理、本地化的細胞療法的生產。這些舉措共同表明，市場正小規模規模、手工製造轉向更標準化、可貿易化且更具投資價值的工業領域。
成長驅動力－支持市場擴張的因素
細胞療法生產市場的成長主要得益於臨床研發管線的快速擴張。根據產業研究機構統計，目前有超過2,100種基因療法候選藥物（包括CAR-T等基因修飾細胞療法）和近1,000種非基因修飾細胞療法正在積極研發中。這種持續的研發管線擴張直接轉化為對專業臨床和商業規模生產能力的需求。
此外，致力於降低細胞療法成本的公司，以及政府支持的在印度和沙烏地阿拉伯等市場的設施投資，正在將生產能力擴展到北美和歐洲以外的傳統地區。從長遠來看，這一趨勢將擴大設備、耗材和物流合作夥伴的潛在市場。
市場挑戰－阻礙進展的主要障礙
儘管市場基本面強勁，仍面臨許多阻礙成長的挑戰。細胞療法從實驗室規模向商業化規模的轉化受到熟練生物製程專家短缺、監管要求不斷變化以及GMP生產能力有限的限制。
此外，由於細胞療法生產需要符合GMP標準的無塵室和嚴格的品管，因此規模化生產仍然是一項重大挑戰，會增加成本、延長生產週期並提高生產複雜性。彌合人才、基礎設施和法規方面的差距，是最大限度地發揮市場商業性潛力的關鍵。
關稅對國內生產的影響
對藥品進口徵收關稅引發了一系列旨在擴大美國國內藥品生產規模的協議和資本投資。今年5月，美國商務部啟動了一項程序，允許藥品生產商申請232條款下的關稅減免，前提是他們承諾擴大或將生產業務遷至美國國內。預計這項政策轉變將促進對國內先進治療藥物生產基礎設施的持續投資。
細胞療法製造市場—關鍵洞察
本報告詳細分析了細胞療法生產市場的現狀，並指出了該行業內的潛在成長機會，尤其從分銷商和通路合作夥伴的觀點。主要發現包括：
- 臨床研發管線發展勢頭強勁：全球有超過 2000 項正在進行的臨床試驗推動細胞療法的發展，維持對臨床和商業生產能力的長期需求。
- 加速製造業夥伴關係：過去五年中，已宣布了 150 多項策略合作，其中許多合作專注於製造、製程開發和技術整合。
- 擴大生產能力仍然是一項至關重要的成長策略：領先的CDMO和生物製藥公司繼續在北美、歐洲和亞太地區投資建造新的GMP生產設施，以滿足預期的商業性需求。
- 自動化正在加速發展：封閉式系統和自動化製造平台的日益普及提高了可擴展性，降低了污染風險，並降低了製造成本。
- 轉向異體細胞療法：目前，生產需求主要集中在自體細胞療法上，但異體細胞療法有望更快地普及，因為它可以「即買即用」（開箱即用）。
- 腫瘤學持續主導：腫瘤學仍然是最大的治療領域，佔細胞療法臨床計畫的大部分，但自體免疫疾病和神經系統疾病也正在成為高成長的應用領域。
- 北美保持主導地位：在強大的開發商基礎、成熟的CDMO和良好的投資環境的支持下，該地區繼續佔製造業活動的最大佔有率。
- 投資活動依然強勁：創業投資、策略性資金籌措和政府支持持續加速加強製造基礎設施和先進細胞療法的商業化。
細胞療法生產市場的細分
Roots Analysis 根據以下參數對全球細胞療法製造市場機會進行分類：
按類型分類的細胞療法
- CAR-T細胞療法
- 幹細胞療法
- TCR療法
- TIL療法
- 樹突細胞療法
- 其他
細胞起源
- 自體細胞
- 同種異體細胞
細胞起源
- 誘導性多功能幹細胞
- 骨髓
- 臍帶
- 脂肪組織
- 神經幹細胞
- 其他
透過技術
- 體細胞技術
- 3D生物列印技術
- 細胞永生化技術
- 病毒載體技術
- 基因組編輯技術
- 細胞可塑性技術
按營運規模
- 臨床量表
- 商業規模
按製造商類型
- 內部製造
- 委託製造
按主要區域
- 北美洲
- 美國
- 加拿大
- 歐洲
- 法國
- 德國
- 義大利
- 西班牙
- 英國
- 其他歐洲國家
- 亞太地區及世界其他地區
- 阿根廷
- 澳洲
- 巴西
- 中國
- 印度
- 以色列
- 日本
- 新加坡
- 南非
- 韓國
- 台灣
細胞療法製造市場－關鍵細分市場分析
CAR-T細胞療法正在推動市場發展。
根據Roots Analysis的市場估值和詳細的臨床研發管線分析，CAR-T細胞療法目前佔最大的市場佔有率。其主導地位得益於CAR-T療法在骨髓惡性腫瘤不斷擴大的臨床和商業性應用、日益豐富的已通過核准產品組合，以及CAR-T療法複雜的生產流程，所有這些因素都顯著提升了其整體市場價值。
展望未來，包括自然殺手 (NK) 細胞療法和基因修飾細胞療法在內的其他細胞療法領域預計將在預測期內實現最高的複合年成長率 (CAGR)。這一成長主要得益於對下一代細胞療法平台投資的增加，旨在提高生產規模、降低生產成本並擴大患者群體。其中，自然殺手 (NK) 細胞療法因其可進行同種異體移植、良好的安全性、較低的移植物抗宿主疾病 (GVHD) 風險以及適合現成生產等優勢而發展勢頭強勁。
自體細胞仍是主要的細胞來源。
根據我們的市場分析，自體細胞療法佔最大的市場佔有率，預計在預測期內將保持最高的複合年成長率。這一成長主要得益於患者特異性療法（尤其是CAR-T細胞療法）在臨床上的日益普及。由於自體療法使用患者自身的細胞，因此可以降低免疫排斥和移植物抗宿主疾病的風險。近期自體幹細胞基因療法的核准進一步凸顯了此療法持續重要的臨床意義。
就細胞來源而言，骨髓是最常見的，而iPS細胞預計生長速度最快。
從細胞來源來看，骨髓來源細胞目前佔最大的市場佔有率。這種主導地位源自於其在造血幹細胞移植領域長期應用的歷史以及成熟的採集、處理和儲存流程。然而，預計在預測期內，誘導性富潛能幹細胞細胞（iPS細胞）將呈現最高的成長速度。這種顯著的成長歸功於iPS細胞能夠無限增殖並分化成多種特化細胞類型，這項特性使其非常適合標準化、同種異體、即用型的生產模式。
體細胞技術在市場上佔主導地位，而 3D 生物列印的複合年成長率更高。
目前，體細胞技術佔最大的市場佔有率。其高市佔率主要歸功於體細胞技術在CAR-T、TCR、樹突狀細胞和幹細胞療法的分離、處理、增殖和修飾等工作流程中的廣泛應用。在所有技術領域中，3D生物列印技術預計將呈現最高的成長速度，這主要得益於人們對用於下一代再生醫學應用的個人化、組織模擬的含細胞結構日益成長的興趣。
臨床規模生產正在推動市場發展，而商業規模生產則實現了更高的複合年成長率。
目前，臨床規模生產佔了最大的市場佔有率，反映出大量候選藥物仍處於早期和晚期臨床試驗階段。隨著更多細胞療法走向核准和商業化，預計未來商業規模生產能力將以更高的複合年成長率成長，這需要對無塵室基礎設施和自動化進行持續的資本投資。
委託製造（CDMO）佔市場主導地位。
目前，CDMO（合約研發生產機構）佔了大部分市場收入佔有率。外包使研發公司能夠降低資本支出、縮短臨床和商業化週期、利用先進的製造技術，並更有效地應對複雜的監管要求。相較之下，內部生產仍集中在大型的、垂直整合的細胞治療公司，這些公司擁有足夠的財力和技術專長來建立和營運符合GMP規範的專用生產設施。
北美市場佔主導地位，並錄得最高的複合年成長率。
目前，北美佔細胞療法生產市場最大的佔有率。這一主導地位得益於北美地區高度集中的細胞療法研發公司、先進的GMP生產基礎設施、完善的臨床研究網路以及柔軟性法規環境。預計該地區在預測期內也將維持最高的複合年成長率。這一前所未有的成長是由持續的產能擴張所驅動的，包括新興企業和成熟企業為在美國東北部地區建立下一代製造地而進行的大規模設施投資。
細胞治療製造市場主要公司示例
- Advanced Therapies
- AGC Biologics
- Astellas Pharma
- Catalent
- Charles River Laboratories
- City of Hope
- Clinical Cell and Vaccine Production Facility（CVPF）
- Evotec
- Fraunhofer Institute for Cell Therapy and Immunology
- ImmunityBio
- Lonza
- Merck Millipore
- Miltenyi Biotec
- Minaris Advanced Therapies
- Newcastle Advanced Therapies
- NHS Blood and Transplant
- OBiO Tech
- Pharmaron
- Rayne Cell Therapy Suite
- Resilience
- Sartorius
- Scottish National Blood Transfusion Service（SNBTS）Cellular Therapy Facility
- SK pharmteco（Subsidiary of SK Inc.）
- Takara Bio
- Thermo Fisher Scientific
專家訪談和行業洞察
本研究中提出的觀點和見解是基於與多位相關人員的討論。本研究報告包含與以下產業相關人員的詳細訪談記錄：
- 一家英國中型公司的執行長
- 美國某大型公司生物製程事業部集團執行官
- 美國某大型公司前技術長
- 美國一家中型公司的副總裁兼品質與合規主管。
- 美國某大型企業細胞與基因治療部門全球科學組合管理執行總監。
- 美國紅十字會輸血醫學教授
- 美國中小企業高級療法事業部銷售資深總監
- 德國一家領先公司製程開發服務部門資深研究員
目錄
第1章：序言
第2章：調查方法
第3章 市場動態
第4章 宏觀經濟指標
- 章節概要
- 市場動態
- 結論
第5章摘要整理
- 摘要整理：市場狀況
- 摘要整理：市場趨勢
- 摘要整理：市場預測與機會分析
第6章：引言
- 章節概要
- 細胞療法簡介
- 細胞療法與其他生物技術產品的比較
- 先進治療藥物（ATMP）的分類
- ATMP 的當前市場狀況
- 細胞治療生產概述
- 細胞療法生產模式
- 集中式製造
- 分散式製造
- 細胞治療生產過程的擴充性
- 擴大規模
- 橫向擴展
- 細胞療法生產商類型
- 細胞療法生產的主要挑戰
- 影響細胞治療產生的主要因素
- 細胞表徵
- 產品成本
- 細胞治療生產自動化
- 細胞療法生產供應鏈
- 未來展望
第7章 細胞療法生產者（參與企業）：市場狀況
- 章節概要
- 業內相關人員：市場狀況
第8章 細胞療法生產者（產業外公司）：市場狀況
- 章節概要
- 外部參與企業該產業：市場狀況
第9章 監理情勢
- 章節概要
- 現狀
- 細胞療法生產的監管機構
- 細胞療法早期生產指南摘要
- 細胞治療生產早期階段所面臨的挑戰
- 各地區監管準則存在差異。
第10章案例研究：克服細胞療法生產相關挑戰的藍圖
- 章節概要
- 美國藍圖
- 通往其他地區的藍圖
- 歐洲
- 亞太地區
第11章案例研究：細胞治療生產中的自動化技術
- 章節概要
- 細胞治療生產過程的自動化
- 生長促進劑和阻礙因素
- 案例研究
第12章 公司概況：參與企業
- 章節概要
- 北美服務供應商
- Advanced Therapies
- Similar details are presented for other below mentioned players based on information in the public domain
- AGC Biologics
- Catalent
- Charles River Laboratories
- ImmunityBio
- Merck Millipore
- Minaris Advanced Therapies
- Resilience
- SK pharmteco（Subsidiary of SK Inc.）
- Thermo Fisher Scientific
- 歐洲服務供應商
- Evotec
- Lonza
- Miltenyi Biotec
- Sartorius
- 亞太地區的服務供應商
- Astellas Pharma
- OBiO Tech
- Pharmaron
- Takara Bio
第13章 公司簡介：產業外的公司
- 章節概要
- City of Hope
- Clinical Cell and Vaccine Production Facility（CVPF）
- Fraunhofer Institute for Cell Therapy and Immunology
- Newcastle Advanced Therapies
- NHS Blood and Transplant
- Rayne Cell Therapy Suite（King's College London）
- Scottish National Blood Transfusion Service（SNBTS）Cellular Therapy Facility
第14章 細胞治療製造領域的非營利組織
- 章節概要
- 細胞療法生產：非營利組織
- 細胞療法製造：國際會議
第15章：臨床試驗分析
- 章節概要
- 研究範圍和調查方法
- 細胞療法：臨床試驗分析
第16章夥伴關係與合作
- 章節概要
- 夥伴關係模式
- 細胞療法生產：合作夥伴列表
- 提供的免疫細胞類型分析
- 按企業規模分析
- 最活躍的參與企業：以夥伴關係數量分析
- 區域分析
第17章 近期擴張
- 章節概要
- 擴充類型
- 細胞療法製造業：近期業務擴張
第18章：主要製藥公司的舉措
- 章節概要
- 細胞療法生產：主要製藥公司名單
- 細胞療法生產：主要製藥公司的一系列舉措
第19章：產能分析
- 章節概要
- 業內相關人員：關鍵假設與調查方法
- 外部參與企業：關鍵先決條件和調查方法
- 結論
第20章 需求分析
- 章節概要
- 先決條件和調查方法
- 全球對細胞療法生產的需求
- 全球對細胞療法生產的臨床需求
- 全球對細胞療法生產的商業需求
第21章：成本價格分析
- 章節概要
- 導致細胞療法成本高的因素
- 細胞療法的定價模型
- 細胞療法的成本最佳化
- 委託製造在細胞治療中的作用
- 細胞療法中的報銷考量
第22章：製造與採購之間的決策架構
- 章節概要
- 前提條件和關鍵參數
- 細胞治療藥物的生產：內部生產與外包之間的決策。
第23章 細胞治療製造組織的總擁有成本
第24章 SWOT分析
第25章：研究與分析
- 章節概要
- 依職位對受訪者進行分析
- 依細胞療法類型分析
- 按企業規模分析
- 按細胞來源分析
- 細胞培養系統類型特異性分析
- 對灌裝和精加工服務可用性的性別分析
第26章：全球細胞療法製造市場
- 章節概要
- 先決條件和調查方法
- 全球細胞療法製造市場－歷史趨勢（2023年至今）及預測（至2035年）
- 市場成長根源分析觀點
- 情境分析
- 主要市場區隔
第27章：細胞療法製造市場（依細胞療法類型分類）
第28章：細胞療法生產市場（依細胞來源分類）
第29章：細胞療法生產市場（依細胞來源分類）
第30章 細胞療法製造市場（依技術分類）
第31章 細胞療法製造市場（依企業規模分類）
第32章：細胞療法製造市場（依製造商類型分類）
第33章 細胞療法製造市場（按主要地區分類）
第34章 細胞療法製造市場機會分析：北美
第35章 細胞療法製造市場機會分析：歐洲
第36章 細胞治療製造市場機會分析：亞太及其他地區
第37章 結論
第38章：高階主管洞察
第39章附錄一：表格形式數據
第40章 附錄二：公司與組織列表
Product Code: RA100392
CELL THERAPY MANUFACTURING MARKET: OVERVIEW
As per Roots Analysis, the global cell therapy manufacturing market is estimated to grow from USD 7.2 billion in the current year to USD 14.0 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 7.7% during the forecast period.
Cell Therapy Manufacturing Market: Growth and Trends
Cell-based therapies have emerged as one of the most clinically transformative modalities in modern medicine. There are more than 1,000 cell and gene therapy candidates under active investigation, and close to 45 cell-based therapies have already been approved by regulatory authorities worldwide. As the treatment class matures from a patient-specific intervention into a scalable therapeutic category, developers are increasingly shifting to specialized manufacturing partners to increase cell therapy production.
The industry is undergoing a decisive shift toward closed, automated, and standardized manufacturing platforms intended to reduce manual intervention, improve batch-to-batch consistency, and support scale-out production models.
Further, the tariff exposure on pharmaceutical imports has accelerated investment in domestic advanced-therapy manufacturing infrastructure in the US, while emerging economies including India and Saudi Arabia are building local capacity to support affordable, regionally accessible cell therapy production. Collectively, these initiatives point to a market that is shifting from artisanal manufacturing toward a more standardized, distributable, and investable industrial category.
Growth Drivers: Factors Fueling Market Expansion
Growth in the cell therapy manufacturing market is being driven primarily by the rapidly expanding clinical pipeline. As of now, industry trackers identified over 2,100 gene therapy candidates (including genetically modified cell therapies such as CAR-T) and close to 1,000 non-genetically modified cell therapies in active development. This sustained pipeline expansion is translating directly into demand for specialized clinical and commercial scale manufacturing capacity.
Furthermore, companies focused on affordable cell therapy access, together with government-backed facility investments in markets such as India and Saudi Arabia, are extending manufacturing capacity beyond the traditional North American and European hubs. This initiative is widening the addressable market for equipment, consumables, and logistics partners over the long term.
Market Challenges: Critical Barriers Hindering Progress
Despite favourable demand fundamentals, the market faces several challenges that impede growth. The transition of cell-based therapies from laboratory to commercial scale is constrained by a shortage of skilled bioprocessing professionals, evolving regulatory requirements, and limited GMP manufacturing capacity.
Further, scale-up remains a key challenge as cell therapy manufacturing requires GMP-compliant cleanrooms and strict quality controls, increasing costs, timelines, and manufacturing complexity. Addressing these workforce, infrastructure, and regulatory harmonization gaps will be central to unlocking the market's full commercial potential.
Role of Tariffs on Domestic Production
Tariff measures on pharmaceutical imports have prompted a wave of agreements and capital commitments aimed at expanding US-based manufacturing. In May, the US Commerce Department opened an application process allowing pharmaceutical manufacturers to seek reduced Section 232 tariff rates in exchange for committing to expand or relocate manufacturing operations domestically. This policy shift is expected to reinforce continued investment in onshore advanced-therapy manufacturing infrastructure.
Cell Therapy Manufacturing Market: Key Insights
The report delves into the current state of the Cell Therapy Manufacturing market and identifies potential growth opportunities within the industry, particularly from a distributor and channel-partner perspective. Some key findings include:
- Clinical Pipeline Momentum: Over 2,000+ active clinical trials are advancing cell therapies globally, sustaining long-term demand for clinical and commercial manufacturing capacity.
- Manufacturing Partnerships Accelerating: More than 150 strategic collaborations have been announced in the past five years, primarily focused on manufacturing, process development, and technology integration.
- Capacity Expansion Remains a Key Growth Strategy: Leading CDMOs and biopharma companies continue to invest in new GMP manufacturing facilities across North America, Europe, and Asia-Pacific to address anticipated commercial demand.
- Automation Gaining Traction: Increasing adoption of closed-system and automated manufacturing platforms is improving scalability, reducing contamination risk, and lowering manufacturing costs.
- Shift Toward Allogeneic Manufacturing: While autologous therapies currently dominate manufacturing demand, allogeneic cell therapies are expected to witness faster adoption owing to their off-the-shelf production potential.
- Oncology Continues To Lead: Oncology remains the largest therapeutic focus, accounting for the majority of cell therapy clinical programs, with autoimmune and neurological disorders emerging as high-growth application areas.
- North America Maintains Leadership: The region continues to account for the largest share of manufacturing activity, supported by a strong developer base, established CDMOs, and favourable investment ecosystem.
- Investment Activity Remains Robust: Venture capital funding, strategic acquisitions, and government support continue to strengthen manufacturing infrastructure and accelerate commercialization of advanced cell therapies.
Cell Therapy Manufacturing Market Segments
Roots Analysis segments the global cell therapy manufacturing market opportunity across the following parameters:
By Type of Cell Therapy
- CAR-T Cell Therapies
- Stem Cell Therapies
- TCR Therapies
- TIL Therapies
- Dendritic Cell Therapies
- Other Cell Therapies
By Source of Cells
- Autologous Cells
- Allogeneic Cells
By Origin of Cells
- Induced Pluripotent Stem Cells
- Bone Marrow
- Umbilical Cord
- Adipose Tissue
- Neural Stem Cells
- Others
By Technology
- Somatic Cell Technology
- 3D Bioprinting Technology
- Cell Immortalization Technology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
By Scale of Operation
- Clinical Scale
- Commercial Scale
By Type of Manufacturer
- In-house Manufacturers
- Contract Manufacturing Organizations
By Key Geographical Regions
- North America
- US
- Canada
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific and Rest of the World
- Argentina
- Australia
- Brazil
- China
- India
- Israel
- Japan
- Singapore
- South Africa
- South Korea
- Taiwan
Cell Therapy Manufacturing Market: Key Segment Insights
CAR-T Cell Therapies Lead the Market
Based on Roots Analysis market assessment and detailed clinical pipeline analysis, CAR-T cell therapies currently hold the highest share of the market. This dominance is driven by strong clinical and commercial adoption in hematological malignancies, an expanding portfolio of approved products, and the complex manufacturing processes associated with CAR-T therapies, which contribute significantly to overall market value.
Looking ahead, the other cell therapies segment including natural killer (NK) cell and genetically modified cell therapies will register the highest CAGR during the forecast period. This growth is driven by rising investment in next-generation cell therapy platforms designed to improve manufacturing scalability, reduce production costs, and expand patient access. Among these, natural killer (NK) cell therapies are gaining significant momentum owing to their allogeneic potential, favorable safety profile, lower risk of graft-versus-host disease, and suitability for off-the-shelf manufacturing.
Autologous Cells Continue to Dominate Source of Cells
According to our market analysis, autologous cells account for the largest share of the market and also register the highest CAGR during the forecast period. This growth is driven by the strong clinical adoption of patient-specific therapies, particularly within CAR-T manufacturing. Since autologous therapies use a patient's own cells, they reduce the risk of immune rejection and graft-versus-host disease. Recent approvals of autologous stem-cell-based gene therapies reinforce the continued clinical relevance of this approach.
Bone Marrow Leads Origin of Cells, iPSCs Poised for Fastest Growth
Bone marrow-derived cells currently account for the largest share of the market by origin of cells. This dominance is due to their long-established use in hematopoietic stem cell transplantation and well-defined collection, processing, and storage protocols. However, induced pluripotent stem cells (iPSCs) are expected to witness the strongest growth over the forecast period. This lucrative growth is due to their capacity to propagate indefinitely and differentiate into multiple specialized cell types, a property well suited to standardized, allogeneic, off-the-shelf manufacturing models.
Somatic Cell Technology Dominates, 3D Bioprinting Registers Higher CAGR
Somatic cell technology currently captures the largest share of the market. This highest share is due to its widespread use across isolation, processing, expansion, and modification workflows for CAR-T, TCR, dendritic cell, and stem cell based therapies. 3D bioprinting technology is expected to grow at the highest rate of any technology segment, driven by rising interest in personalized, tissue-mimetic cell-laden constructs for next-generation regenerative medicine applications.
Clinical-Scale Manufacturing Leads the Market While Commercial Scale Register Higher CAGR
Clinical-scale manufacturing currently captures the largest share of the market, reflecting the sheer volume of candidates still progressing through early and late stage trials. As more cell therapies advance toward approval and commercial launch, commercial-scale manufacturing capacity is expected to expand at a higher CAGR in the future, requiring sustained capital investment in cleanroom infrastructure and automation.
Contract Manufacturing Organizations Capture the Majority Share
CDMOs currently account for the majority of overall market revenue share. Outsourcing enables developers to reduce capital expenditure, accelerate clinical and commercial timelines, access advanced manufacturing technologies, and navigate complex regulatory requirements more efficiently. In contrast, in-house manufacturing remains concentrated among large, vertically integrated cell therapy companies with financial resources and technical expertise to establish and operate dedicated GMP-compliant manufacturing facilities.
North America Dominates the Market and Registers the Highest CAGR
North America currently captures the largest share of the cell therapy manufacturing market. This highest share is supported by a dense concentration of cell therapy developers, advanced GMP manufacturing infrastructure, established clinical research networks, and an increasingly flexible regulatory environment in the US. The region is also expected to register the fastest CAGR over the forecast period. This unprecedented growth is driven by continued capacity expansion including large-scale facility investments announced by both emerging and established players seeking next-generation manufacturing footprint in the US Northeast.
Example Players in Cell Therapy Manufacturing Market
- Advanced Therapies
- AGC Biologics
- Astellas Pharma
- Catalent
- Charles River Laboratories
- City of Hope
- Clinical Cell and Vaccine Production Facility (CVPF)
- Evotec
- Fraunhofer Institute for Cell Therapy and Immunology
- ImmunityBio
- Lonza
- Merck Millipore
- Miltenyi Biotec
- Minaris Advanced Therapies
- Newcastle Advanced Therapies
- NHS Blood and Transplant
- OBiO Tech
- Pharmaron
- Rayne Cell Therapy Suite
- Resilience
- Sartorius
- Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
- SK pharmteco (Subsidiary of SK Inc.)
- Takara Bio
- Thermo Fisher Scientific
Expert Interview and Industry Insights
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
- Chief Executive Officer, Mid-sized Company, UK
- Group Executive, Bioprocess, Very Large Company, US
- Former Chief Technical Officer, Large Company, US
- Vice President & Head of Quality & Compliance, Mid-sized Company, US
- Executive Director, Global Scientific Portfolio Management, Cell and Gene Therapy, Very Large Company, US
- Professor and American Red Cross Chair in Transfusion Medicine, US
- Senior Director of Sales, Advanced Therapies, Small Company, US
- Principal Scientist, Process Development Services, Very Large Company, Germany
CELL THERAPY MANUFACTURING MARKET: RESEARCH COVERAGE
- Market Sizing and Opportunity Analysis: An in-depth, top-down and bottom-up triangulated analysis of the market focusing on key segments, including type of cell therapy, source of cells, origin of cells, technology, scale of operation, type of manufacturer, and geographical regions.
- Industry and Non-Industry Player Landscape: A detailed assessment of both commercial (industry) and academic / non-profit (non-industry) cell therapy manufacturers, featuring year of establishment, company size, location of headquarters and manufacturing facilities, type of immune cell offered, source of cells, and scale of operation.
- Regulatory Landscape: A review of current regulatory guidelines across North America, Europe, and Asia-Pacific, including conditional approval pathways and the variability in requirements across geographies.
- Case Study I (Roadmaps for Overcoming Manufacturing Challenges): A focused assessment of roadmaps for cell processing, preservation, automation, quality control, standardization, workforce development, and supply chain across the US and other geographies.
- Case Study II (Automation Technologies): An evaluation of closed, single-use, and modular automation systems, including growth drivers, roadblocks, and case studies of automated manufacturing device development.
- Company Profiles: In-depth profiles of prominent industry and non-industry players, covering company overview, financial information, service portfolio, manufacturing facilities and capabilities, and recent developments.
- Non-Profit Organizations: An overview of non-profit and consortium-based cell therapy manufacturing initiatives and international societies active in the domain.
- Clinical Trial Analysis: A comprehensive analysis of cell therapy clinical trials by registration year, status, phase, study design, sponsor type, most active players, and geography.
- Partnerships and Collaborations: An analysis of partnerships inked by cell therapy manufacturers, based on year, type of partnership, type of immune cell, scale of operation, most active players, and geography.
- Recent Expansions Analysis: A comprehensive assessment of recent facility expansion initiatives by type, year, location, and immune cell focus, identifying the most active companies by number of expansions and area added.
- Big Pharma Initiatives: An analysis of initiatives undertaken by leading pharmaceutical companies, covering partnerships, M&A, facility expansions, and funding activity, and identifying the most active big pharma players.
- Capacity Analysis: A comprehensive assessment of global installed cleanroom capacity (number and area) across company size, scale of operation, and geography, for both industry and non-industry players.
- Demand Analysis: An evaluation of global clinical and commercial demand for cell therapy manufacturing, segmented by type of cell therapy and geography.
- Cost Price Analysis: An assessment of the factors driving high cell therapy pricing, pricing models, cost optimization levers, the role of CDMOs, and reimbursement considerations, including a NICE CAR-T appraisal case study.
- SWOT Analysis: A strategic assessment of the market's strengths, weaknesses, opportunities, and threats, with a comparative Harvey Ball analysis.
- Survey Analysis: Primary survey insights on respondent designation, type of cell therapy, scale of operation, source of cells, cell culture system, and fill / finish service availability.
- Executive Insights: Company snapshots and interview transcripts capturing the perspectives of senior industry and non-industry stakeholders.
Key Questions Answered in this Report
- Which are the leading companies in the cell therapy manufacturing market?
- Which region dominates the market, and which is growing the fastest?
- What are the key trends observed in this market?
- What factors are likely to influence the evolution of this market?
- What are the primary challenges faced by cell therapy manufacturers?
- What is the current and future market size?
- What is the CAGR of this market through 2035?
- How is current and future market opportunity distributed across key segments?
- What opportunities exist for distributors and logistics partners entering this space?
Reasons to Buy this Report
This report has been specifically developed to support distributors, channel partners, and business development teams evaluating entry into the cell therapy manufacturing market.
- Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates top-down macro assessments against bottom-up, company-level capacity and demand data, minimizing forecast bias.
- 656 Pages Across 40 Chapters: Comprehensive coverage spanning market sizing, competitive benchmarking, clinical trial activity, capacity, demand, funding and M&A analysis, and regulatory mapping across 25+ countries.
- Primary Research-Backed Insights: Findings are validated through direct interviews with CEOs, CTOs, and commercial leaders across 34 industry and non-industry organizations, ensuring insights reflect real operating conditions rather than desk research alone.
- Actionable Segmentation: Seven-parameter segmentation (type of cell therapy, source of cells, origin of cells, technology, scale of operation, type of manufacturer, geography) enables precise opportunity sizing for any go-to-market or investment thesis.
Additional Benefits
- Complementary Insights Pack
- Complementary PPT Insights Pack
- Complementary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
TABLE OF CONTENTS
1. PREFACE
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
- 2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
- 2.4. Project Methodology
- 2.4.1. Secondary Research
- 2.4.1.1. Annual Reports
- 2.4.1.2. Academic Research Papers
- 2.4.1.3. Company Websites
- 2.4.1.4. Investor Presentations
- 2.4.1.5. Regulatory Filings
- 2.4.1.6. White Papers
- 2.4.1.7. Industry Publications
- 2.4.1.8. Conferences and Seminars
- 2.4.1.9. Government Portals
- 2.4.1.10. Media and Press Releases
- 2.4.1.11. Newsletters
- 2.4.1.12. Industry Databases
- 2.4.1.13. Roots Proprietary Databases
- 2.4.1.14. Paid Databases and Sources
- 2.4.1.15. Social Media Portals
- 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
- 2.4.2.1. Types of Primary Research
- 2.4.2.1.1. Qualitative Research
- 2.4.2.1.2. Quantitative Research
- 2.4.2.1.3. Hybrid Approach
- 2.4.2.2. Advantages of Primary Research
- 2.4.2.3. Techniques for Primary Research
- 2.4.2.3.1. Interviews
- 2.4.2.3.2. Surveys
- 2.4.2.3.3. Focus Groups
- 2.4.2.3.4. Observational Research
- 2.4.2.3.5. Social Media Interactions
- 2.4.2.4. Key Opinion Leaders Considered in Primary Research
- 2.4.2.4.1. Company Executives (CXOs)
- 2.4.2.4.2. Board of Directors
- 2.4.2.4.3. Company Presidents and Vice Presidents
- 2.4.2.4.4. Research and Development Heads
- 2.4.2.4.5. Technical Experts
- 2.4.2.4.6. Subject Matter Experts
- 2.4.2.4.7. Scientists
- 2.4.2.4.8. Doctors and Other Healthcare Providers
- 2.4.2.5. Ethics and Integrity
- 2.4.2.5.1. Research Ethics
- 2.4.2.5.2. Data Integrity
- 2.4.2.1. Types of Primary Research
- 2.4.3. Analytical Tools and Databases
- 2.4.1. Secondary Research
- 2.5. Robust Quality Control
3. MARKET DYNAMICS
- 3.1. Chapter Overview
- 3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
- 3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
- 3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
- 3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
- 3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
- 4.1. Chapter Overview
- 4.2. Market Dynamics
- 4.2.1. Time Period
- 4.2.1.1. Historical Trends
- 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
- 4.2.2.1. Major Currencies Affecting the Market
- 4.2.2.2. Factors Affecting Currency Fluctuations
- 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
- 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
- 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
- 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
- 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
- 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
- 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
- 4.2.6.1. Interest Rates and Their Impact on the Market
- 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
- 4.2.7.1. Type of Commodity
- 4.2.7.2. Origins and Destinations
- 4.2.7.3. Values and Weights
- 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
- 4.2.8.1. Import Scenario
- 4.2.8.2. Export Scenario
- 4.2.8.3. Trade Policies
- 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
- 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
- 4.2.9.1. Russian-Ukraine War
- 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
- 4.2.10.1. Global Economic Impact
- 4.2.10.2. Industry-specific Impact
- 4.2.10.3. Government Response and Stimulus Measures
- 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
- 4.2.11.1. Fiscal Policy
- 4.2.11.2. Consumer Spending
- 4.2.11.3. Gross Domestic Product
- 4.2.11.4. Employment
- 4.2.11.5. Taxes
- 4.2.11.6. Stock Market Performance
- 4.2.11.7. Cross Border Dynamics
- 4.2.1. Time Period
- 4.3. Conclusion
5. EXECUTIVE SUMMARY
- 5.1. Executive Summary: Market Landscape
- 5.2. Executive Summary: Market Trends
- 5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
- 6.1. Chapter Overview
- 6.2. Introduction to Cell-based Therapies
- 6.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
- 6.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
- 6.2.3. Current Market Landscape of ATMPs
- 6.3. Overview of Cell Therapy Manufacturing
- 6.4. Cell Therapy Manufacturing Models
- 6.4.1. Centralized Manufacturing
- 6.4.2. Decentralized Manufacturing
- 6.5. Scalability of Cell Therapy Manufacturing Processes
- 6.5.1. Scale-up
- 6.5.2. Scale-out
- 6.6. Types of Cell Therapy Manufacturers
- 6.7. Key Challenges for Manufacturing Cell Therapies
- 6.8. Key Factors Influencing Cell Therapy Manufacturing
- 6.8.1. Cell Characterization
- 6.8.2. Cost of Goods
- 6.9. Automation of Cell Therapy Manufacturing
- 6.10. Cell Therapy Manufacturing Supply Chain
- 6.11. Future Perspectives
7. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
- 7.1. Chapter Overview
- 7.2. Industry Players: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters (Region)
- 7.2.4. Analysis by Location of Headquarters (Country)
- 7.2.5. Analysis by Company Size and Location of Headquarters (Region)
- 7.2.6. Analysis by Location of Manufacturing Facility
- 7.2.7. Analysis by Type of Immune Cell Offered
- 7.2.8. Analysis by Source of Cells
- 7.2.9. Analysis by Scale of Operation
- 7.2.10. Analysis by Type of Additional Service Offered
8. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
- 8.1. Chapter Overview
- 8.2. Non-Industry Players: Overall Market Landscape
- 8.2.1. Analysis by Year of Establishment
- 8.2.2. Analysis by Location of Headquarters (Region)
- 8.2.3. Analysis by Location of Headquarters (Country)
- 8.2.4. Analysis by Location of Manufacturing Facility
- 8.2.5. Analysis by Type of Immune Cell Offered
- 8.2.6. Analysis by Source of Cell
- 8.2.7. Analysis by Scale of Operation
- 8.2.8. Analysis by Type of Additional Service Offered
9. REGULATORY LANDSCAPE
- 9.1. Chapter Overview
- 9.2. Current Scenario
- 9.2.1. Regulatory Guidelines in North America
- 9.2.2. Regulatory Guidelines in Europe
- 9.2.3. Regulatory Guidelines in Asia-Pacific
- 9.2.3.1. Regulatory Guidelines in Japan
- 9.2.3.2. Regulatory Guidelines in China
- 9.2.4. Conditional Approvals
- 9.3. Regulatory Authorities for Cell Therapy Manufacturing
- 9.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
- 9.4. Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
- 9.5. Existing Challenges to Early-Stage Manufacturing of Cell Therapies
- 9.6. Variability in Regulatory Guidelines across Different Geographies
10. CASE STUDY: ROADMAPS FOR OVERCOMING CHALLENGES RELATED TO CELL THERAPY MANUFACTURING
- 10.1. Chapter Overview
- 10.2. Roadmap for the US
- 10.2.1. Cell Processing
- 10.2.2. Cell Preservation, Distribution and Handling
- 10.2.3. Process Automation and Data Analytics
- 10.2.4. Process Monitoring and Quality Control
- 10.2.5. Standardization and Regulatory Support
- 10.2.6. Workforce Development
- 10.2.7. Supply Chain and Logistics
- 10.3. Roadmaps for Other Geographies
- 10.3.1. Europe
- 10.3.2. Asia-Pacific
11. CASE STUDY: AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
- 11.1. Chapter Overview
- 11.2. Automation of Cell Therapy Manufacturing Processes
- 11.2.1. Closed Systems
- 11.2.2. Single-use Systems
- 11.2.3. Modular Systems
- 11.3. Growth Drivers and Roadblocks
- 11.4. Case Studies
- 11.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
- 11.4.2. Automating the Cell Therapy Manufacturing Process
- 11.4.3. Advancement to Automation of Cell Therapy Manufacturing Process
- 11.4.4. GMP-in-a-Box
- 11.4.5. List of Automated and Closed Cell Therapy Processing Systems
12. COMPANY PROFILES: INDUSTRY PLAYERS
- 12.1. Chapter Overview
- 12.2. Service Providers in North America
- 12.2.1. Advanced Therapies
- 12.2.1.1. Company Overview
- 12.2.1.2. Financial Information
- 12.2.1.3. Service Portfolio
- 12.2.1.4. Manufacturing Facilities and Capabilities
- 12.2.1.5. Recent Developments and Future Outlook
- Similar details are presented for other below mentioned players based on information in the public domain
- 12.2.2. AGC Biologics
- 12.2.3. Catalent
- 12.2.4. Charles River Laboratories
- 12.2.5. ImmunityBio
- 12.2.6. Merck Millipore
- 12.2.7. Minaris Advanced Therapies
- 12.2.8. Resilience
- 12.2.9. SK pharmteco (Subsidiary of SK Inc.)
- 12.2.10. Thermo Fisher Scientific
- 12.2.1. Advanced Therapies
- 12.3. Service Providers in Europe
- 12.3.1. Evotec
- 12.3.2. Lonza
- 12.3.3. Miltenyi Biotec
- 12.3.4. Sartorius
- 12.4. Service Providers in Asia-Pacific
- 12.4.1. Astellas Pharma
- 12.4.2. OBiO Tech
- 12.4.3. Pharmaron
- 12.4.4. Takara Bio
13. COMPANY PROFILES: NON-INDUSTRY PLAYERS
- 13.1. Chapter Overview
- 13.2. City of Hope
- 13.2.1. Overview
- 13.2.2. Service Portfolio
- 13.2.3. Type of Additional Service Offered
- similar details are presented for other below mentioned players based on information in the public domain
- 13.3. Clinical Cell and Vaccine Production Facility (CVPF)
- 13.4. Fraunhofer Institute for Cell Therapy and Immunology
- 13.5. Newcastle Advanced Therapies
- 13.6. NHS Blood and Transplant
- 13.7. Rayne Cell Therapy Suite (King's College London)
- 13.8. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
14. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING
- 14.1. Chapter Overview
- 14.2. Cell Therapy Manufacturing: Non-Profit Organizations
- 14.2.1. CellCAN
- 14.2.2. Cell Therapy Manufacturing Cooperative Research Center
- 14.2.3. National Cell Manufacturing Consortium (NCMC)
- 14.2.4. California Institute of Regenerative Medicine (CIRM)
- 14.3. Cell Therapy Manufacturing: International Societies
15. CLINICAL TRIAL ANALYSIS
- 15.1. Chapter Overview
- 15.2. Scope and Methodology
- 15.3. Cell Therapies: Clinical Trial Analysis
- 15.3.1. Analysis by Trial Registration Year
- 15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
- 15.3.3. Analysis by Trial Status
- 15.3.4. Analysis by Trial Registration Year and Trial Status
- 15.3.5. Analysis by Trial Phase
- 15.3.6. Analysis of Enrolled Patient Population by Trial Phase
- 15.3.7. Analysis by Patient Gender
- 15.3.8. Analysis by Study Design
- 15.3.8.1. Analysis by Type of Allocation
- 15.3.8.2. Analysis by Intervention Model
- 15.3.8.3. Analysis by Type of Masking
- 15.3.9. Analysis by Type of Sponsor / Collaborator
- 15.3.10. Most Active Players: Analysis by Number of Registered Trials
- 15.3.11. Analysis by Geography
- 15.3.11.1. Analysis of Clinical Trials by Geography
- 15.3.11.2. Analysis of Clinical Trials by Trial Status and Geography
- 15.3.11.3. Analysis of Enrolled Patient Population by Trial Status and Geography
16. PARTNERSHIPS AND COLLABORATIONS
- 16.1. Chapter Overview
- 16.2. Partnership Models
- 16.3. Cell Therapy Manufacturing: List of Partnerships
- 16.3.1. Analysis by Year of Partnership
- 16.3.2. Analysis by Type of Partnership
- 16.3.3. Analysis by Year and Type of Partnership
- 16.4. Analysis by Type of Immune Cell Offered
- 16.5. Analysis by Scale of Operation
- 16.6. Most Active Players: Analysis by Number of Partnerships
- 16.7. Analysis by Geography
- 16.7.1. Local and International Agreements
- 16.7.2. Intracontinental and Intercontinental Agreements
17. RECENT EXPANSIONS
- 17.1. Chapter Overview
- 17.2. Type of Expansions
- 17.3. Cell Therapy Manufacturing: Recent Expansions
- 17.3.1. Analysis by Year of Expansion
- 17.3.2. Analysis by Type of Expansion
- 17.3.3. Analysis by Year and Type of Expansion
- 17.3.4. Analysis by Location of Expanded Facility (Region)
- 17.3.5. Analysis by Location of Expanded Facility (Country)
- 17.3.6. Analysis by Type of Expansion and Location of Headquarters (Country)
- 17.3.7. Analysis by Type of Immune Cell Offered
- 17.3.8. Analysis by Type of Expansion and Type of Immune Cell Offered
- 17.3.9. Analysis by Scale of Operation
- 17.3.10. Most Active Players: Analysis by Number of Expansions
- 17.3.11. Most Active Players: Analysis by Area of Expansion
18. BIG PHARMA INITIATIVES
- 18.1. Chapter Overview
- 18.2. Cell Therapy Manufacturing: List of Big Pharma Players
- 18.3. Cell Therapy Manufacturing: List of Initiatives by Big Pharma Players
- 18.3.1. Analysis by Year of Initiative
- 18.3.2. Analysis by Type of Initiative
- 18.3.3. Analysis by Year and Type of Initiative
- 18.3.4. Big Players: Analysis by Number of Initiatives
- 18.3.5. Analysis by Type of Partnership
- 18.3.6. Big Players: Analysis by Number of Partnerships
- 18.3.7. Analysis by Type of Facility Expansion
- 18.3.8. Big Players: Analysis by Number of Facility Expansions
- 18.3.9. Big Players: Analysis by Region of Facility Expansion
- 18.3.10. Big Players: Analysis by Number of Mergers and Acquisitions
- 18.3.11. Big Players: Analysis by Number of Funding and Investment
- 18.3.12. Analysis by Type of Immune Cell Offered
- 18.3.13. Analysis by Scale of Operation
- 18.3.14. Analysis of Big Pharma Players by Scale of Operation
- 18.3.15. Big Pharma Initiatives Summary
19. CAPACITY ANALYSIS
- 19.1. Chapter Overview
- 19.2. Industry Players: Key Assumptions and Methodology
- 19.2.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
- 19.2.1.1. Analysis by Company Size
- 19.2.1.2. Analysis by Scale of Operation
- 19.2.1.3. Analysis by Location of Manufacturing Facility
- 19.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
- 19.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
- 19.2.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
- 19.2.2.1. Analysis by Company Size
- 19.2.2.2. Analysis by Scale of Operation
- 19.2.2.3. Analysis by Location of Manufacturing Facility
- 19.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
- 19.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility
- 19.2.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
- 19.3. Non-Industry Players: Key Assumptions and Methodology
- 19.3.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
- 19.3.1.1. Analysis by Scale of Operation
- 19.3.1.2. Analysis by Location of Manufacturing Facility
- 19.3.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
- 19.3.2.1. Analysis by Scale of Operation
- 19.3.2.2. Analysis by Location of Manufacturing Facility
- 19.3.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
- 19.4. Concluding Remarks
20. DEMAND ANALYSIS
- 20.1. Chapter Overview
- 20.2. Assumptions and Methodology
- 20.3. Global Demand for Cell Therapy Manufacturing
- 20.4. Global Clinical Demand for Cell Therapy Manufacturing
- 20.4.1. Clinical Demand: Analysis by Type of Cell Therapy
- 20.4.2. Clinical Demand: Analysis by Geography
- 20.5. Global Commercial Demand for Cell Therapy Manufacturing
- 20.5.1. Commercial Demand: Analysis by Type of Cell Therapy
- 20.5.2. Commercial Demand: Analysis by Geography
21. COST PRICE ANALYSIS
- 21.1. Chapter Overview
- 21.2. Factors Contributing to the High Price of Cell Therapies
- 21.3. Pricing Models for Cell Therapies
- 21.3.1. Based on Associated Costs for T-cell Therapies
- 21.3.2. Based on Associated Costs for Stem Cell Therapies
- 21.3.3. Based on Availability of Competing Products
- 21.3.4. Based on Target Patient Segment
- 21.3.5. Based on the Opinions of Industry Experts
- 21.4. Cell Therapy Cost Optimization
- 21.4.1. Role of Cost of Goods Sold
- 21.4.2. Role of Automation
- 21.5. Role of Cell Therapy Contract Manufacturing Organizations
- 21.6. Reimbursement-related Considerations for Cell Therapies
- 21.6.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies
22. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
- 22.1. Chapter Overview
- 22.2. Assumptions and Key Parameters
- 22.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
- 22.3.1. Scenario 1
- 22.3.2. Scenario 2
- 22.3.3. Scenario 3
- 22.3.4. Scenario 4
23. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS
- 23.1. Chapter Overview
- 23.2. Key Parameters
- 23.3. Assumptions and Methodology
- 23.4. Sample Dataset for the Estimation of Total Cost of Ownership
- 23.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
- 23.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
- 23.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
- 23.6.2. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20
24. SWOT ANALYSIS
- 24.1. Chapter Overview
- 24.2. Strengths
- 24.3. Weaknesses
- 24.4. Opportunities
- 24.5. Threats
- 24.6. Comparison of SWOT Factors
25. SURVEY ANALYSIS
- 25.1. Chapter Overview
- 25.2. Analysis by Designation of Respondents
- 25.3. Analysis by Type of Cell Therapy
- 25.4. Analysis by Scale of Operation
- 25.5. Analysis by Source of Cells
- 25.6. Analysis by Type of Cell Culture System Used
- 25.7. Analysis by Availability of Fill / Finish Services
26. GLOBAL CELL THERAPY MANUFACTURING MARKET
- 26.1. Chapter Overview
- 26.2. Assumptions and Methodology
- 26.3. Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 26.4. Roots Analysis Perspective on Market Growth
- 26.5. Scenario Analysis
- 26.5.1. Conservative Scenario
- 26.5.2. Optimistic Scenario
- 26.6. Key Market Segmentations
27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY
- 27.1. Chapter Overview
- 27.2. Key Assumptions and Methodology
- 27.3. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
- 27.3.1. Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.2. Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.3. Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.4. Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.5. Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.6. Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.4. Data Triangulation and Validation
28. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS
- 28.1. Chapter Overview
- 28.2. Key Assumptions and Methodology
- 28.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells
- 28.3.1. Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 28.3.2. Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 28.4. Data Triangulation and Validation
29. CELL THERAPY MANUFACTURING MARKET, BY ORIGIN OF CELLS
- 29.1. Chapter Overview
- 29.2. Key Assumptions and Methodology
- 29.3. Cell Therapy Manufacturing Market: Distribution by Origin of Cells
- 29.3.1. Cell Therapy Manufacturing Market for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.2. Cell Therapy Manufacturing Market for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.3. Cell Therapy Manufacturing Market for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.4. Cell Therapy Manufacturing Market for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.5. Cell Therapy Manufacturing Market for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.6. Cell Therapy Manufacturing Market for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.4. Data Triangulation and Validation
30. CELL THERAPY MANUFACTURING MARKET, BY TECHNOLOGY
- 30.1. Chapter Overview
- 30.2. Key Assumptions and Methodology
- 30.3. Cell Therapy Manufacturing Market: Distribution by Technology
- 30.3.1. Cell Therapy Manufacturing Market for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.2. Cell Therapy Manufacturing Market for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.3. Cell Therapy Manufacturing Market for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.4. Cell Therapy Manufacturing Market for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.5. Cell Therapy Manufacturing Market for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.6. Cell Therapy Manufacturing Market for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.4. Data Triangulation and Validation
31. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION
- 31.1. Chapter Overview
- 31.2. Key Assumptions and Methodology
- 31.3. Cell Therapy Manufacturing Market: Distribution by Scale of Operation
- 31.3.1. Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 31.3.2. Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 31.4. Data Triangulation and Validation
32. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
- 32.1. Chapter Overview
- 32.2. Key Assumptions and Methodology
- 32.3. Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
- 32.3.1. Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 32.3.2. Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 32.4. Data Triangulation and Validation
33. CELL THERAPY MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
- 33.1. Chapter Overview
- 33.2. Key Assumptions and Methodology
- 33.3. Cell Therapy Manufacturing Market: Distribution by Key Geographical Regions
- 33.3.1. Clinical Cell Therapy Manufacturing Market
- 33.3.1.1. Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.1.1. Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.1.2. Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.2. Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.2.1. Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.2.2. Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.2.3. Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.2.4. Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.2.5. Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3. Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.1. Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.2. Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.3. Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.4. Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.5. Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.6. Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.7. Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.8. Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.3.9. Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1.1. Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2. Commercial Cell Therapy Manufacturing Market
- 33.3.2.1. Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.1.1. Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.1.2. Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.2. Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.2.1. Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.2.2. Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.2.3. Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.2.4. Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.2.5. Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.2.6. Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.3. Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.3.1. Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.3.2. Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.3.3. Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.3.4. Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.3.5. Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.3.6. Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2.1. Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.1. Clinical Cell Therapy Manufacturing Market
- 33.4. Penetration Growth (P-G) Matrix
- 33.5. Market Dynamics Assessment
34. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
- 34.1. Cell Therapy Manufacturing Market in North America: Distribution by Type of Cell Therapy
- 34.1.1. Cell Therapy Manufacturing Market in North America for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.2. Cell Therapy Manufacturing Market in North America for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.3. Cell Therapy Manufacturing Market in North America for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.4. Cell Therapy Manufacturing Market in North America for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.5. Cell Therapy Manufacturing Market in North America for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.6. Cell Therapy Manufacturing Market in North America for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.2. Cell Therapy Manufacturing Market in North America: Distribution by Source of Cells
- 34.2.1. Cell Therapy Manufacturing Market in North America for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.2.2. Cell Therapy Manufacturing Market in North America for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3. Cell Therapy Manufacturing Market in North America: Distribution by Origin of Cells
- 34.3.1. Cell Therapy Manufacturing Market in North America for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.2. Cell Therapy Manufacturing Market in North America for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.3. Cell Therapy Manufacturing Market in North America for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.4. Cell Therapy Manufacturing Market in North America for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.5. Cell Therapy Manufacturing Market in North America for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.6. Cell Therapy Manufacturing Market in North America for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4. Cell Therapy Manufacturing Market in North America: Distribution by Technology
- 34.4.1. Cell Therapy Manufacturing Market in North America for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.2. Cell Therapy Manufacturing Market in North America for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.3. Cell Therapy Manufacturing Market in North America for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.4. Cell Therapy Manufacturing Market in North America for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.5. Cell Therapy Manufacturing Market in North America for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.6. Cell Therapy Manufacturing Market in North America for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.5. Cell Therapy Manufacturing Market in North America: Distribution by Scale of Operation
- 34.5.1. Cell Therapy Manufacturing Market in North America for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.5.2. Cell Therapy Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.6. Cell Therapy Manufacturing Market in North America: Distribution by Type of Manufacturer
- 34.6.1. Cell Therapy Manufacturing Market in North America for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.6.2. Cell Therapy Manufacturing Market in North America for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: EUROPE
- 35.1. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Cell Therapy
- 35.1.1. Cell Therapy Manufacturing Market in Europe for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.2. Cell Therapy Manufacturing Market in Europe for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.3. Cell Therapy Manufacturing Market in Europe for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.4. Cell Therapy Manufacturing Market in Europe for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.5. Cell Therapy Manufacturing Market in Europe for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.6. Cell Therapy Manufacturing Market in Europe for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.2. Cell Therapy Manufacturing Market in Europe: Distribution by Source of Cells
- 35.2.1. Cell Therapy Manufacturing Market in Europe for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.2.2. Cell Therapy Manufacturing Market in Europe for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3. Cell Therapy Manufacturing Market in Europe: Distribution by Origin of Cells
- 35.3.1. Cell Therapy Manufacturing Market in Europe for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.2. Cell Therapy Manufacturing Market in Europe for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.3. Cell Therapy Manufacturing Market in Europe for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.4. Cell Therapy Manufacturing Market in Europe for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.5. Cell Therapy Manufacturing Market in Europe for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.6. Cell Therapy Manufacturing Market in Europe for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4. Cell Therapy Manufacturing Market in Europe: Distribution by Technology
- 35.4.1. Cell Therapy Manufacturing Market in Europe for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.2. Cell Therapy Manufacturing Market in Europe for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.3. Cell Therapy Manufacturing Market in Europe for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.4. Cell Therapy Manufacturing Market in Europe for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.5. Cell Therapy Manufacturing Market in Europe for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.6. Cell Therapy Manufacturing Market in Europe for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.5. Cell Therapy Manufacturing Market in Europe: Distribution by Scale of Operation
- 35.5.1. Cell Therapy Manufacturing Market in Europe for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.5.2. Cell Therapy Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.6. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Manufacturer
- 35.6.1. Cell Therapy Manufacturing Market in Europe for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.6.2. Cell Therapy Manufacturing Market in Europe for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD
- 36.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Cell Therapy
- 36.1.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Source of Cells
- 36.2.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.2.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Origin of Cells
- 36.3.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Technology
- 36.4.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
- 36.5.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.5.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Manufacturer
- 36.6.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.6.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- *Detailed information on Chapters 34-36 is available in the Excel Data Packs shared along with the report**
37. CONCLUDING REMARKS
38. EXECUTIVE INSIGHTS
39. APPENDIX I: TABULATED DATA
40. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
List of Tables
- Table 6.1 Cell-based Therapies: Applications
- Table 6.2 Differences between Cell Therapy and Biotechnological Products
- Table 6.3 Cell-based Therapies: Commercialized Products
- Table 6.4 Assessment of Cell Therapy Manufacturing Steps
- Table 6.5 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
- Table 7.1 Industry Players: Information on Year of Establishment, Company Size, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
- Table 7.2 Industry Players: Information on Type of Immune Cell Offered
- Table 7.3 Industry Players: Information on Source of Cells and Scale of Operation
- Table 7.4 Industry Players: Information on Type of Additional Service Offered
- Table 8.1 Non-Industry Players: Information on Year of Establishment, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
- Table 8.2 Non-Industry Players: Information on Type of Immune Cell Offered
- Table 8.3 Non-Industry Players: Information on Source of Cell and Scale of Operation
- Table 8.4 Non-Industry Players: Information on Type of Additional Service Offered
- Table 9.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
- Table 9.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
- Table 9.3 Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
- Table 10.1 Cell Therapy Manufacturing: Roadmap for the US
- Table 10.2 Cell Processing: Challenges and Strategies
- Table 10.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
- Table 10.4 Process Monitoring and Quality Control: Challenges and Strategies
- Table 10.5 Standardization and Regulatory Support: Challenges and Strategies
- Table 10.6 Workforce Development: Challenges and Strategies
- Table 10.7 Supply Chain and Logistics: Challenges and Strategies
- Table 10.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
- Table 11.1 Cell Therapy Manufacturing: List of Automated and Closed Cell Therapy Processing Systems
- Table 12.1 Cell Therapy Manufacturing Industry Players: List of Companies Profiled
- Table 12.2 Advanced Therapies: Company Snapshot
- Table 12.3 Advanced Therapies: Information on Manufacturing Facilities and Capabilities
- Table 12.4 Advanced Therapies: Recent Developments and Future Outlook
- Table 12.5 AGC Biologics: Company Snapshot
- Table 12.6 AGC Biologics: Information on Manufacturing Facilities and Capabilities
- Table 12.7 AGC Biologics: Recent Developments and Future Outlook
- Table 12.8 Catalent: Company Snapshot
- Table 12.9 Catalent: Information on Manufacturing Facilities and Capabilities
- Table 12.10 Catalent: Recent Developments and Future Outlook
- Table 12.11 Charles River Laboratories: Company Snapshot
- Table 12.12 Charles River Laboratories: Information on Manufacturing Facilities and Capabilities
- Table 12.13 Charles River Laboratories: Recent Developments and Future Outlook
- Table 12.14 ImmunityBio: Company Snapshot
- Table 12.15 ImmunityBio: Information on Manufacturing Facilities and Capabilities
- Table 12.16 ImmunityBio: Recent Developments and Future Outlook
- Table 12.17 Merck Millipore: Company Snapshot
- Table 12.18 Merck Millipore: Information on Manufacturing Facilities and Capabilities
- Table 12.19 Merck Millipore: Recent Developments and Future Outlook
- Table 12.20 Minaris Advanced Therapies: Company Snapshot
- Table 12.21 Minaris Advanced Therapies: Information on Manufacturing Facilities and Capabilities
- Table 12.22 Minaris Advanced Therapies: Recent Developments and Future Outlook
- Table 12.23 Resilience: Company Snapshot
- Table 12.24 Resilience: Information on Manufacturing Facilities and Capabilities
- Table 12.25 Resilience: Recent Developments and Future Outlook
- Table 12.26 SK pharmteco (Subsidiary of SK Inc.): Company Snapshot
- Table 12.27 SK pharmteco (Subsidiary of SK Inc.): Information on Manufacturing Facilities and Capabilities
- Table 12.28 SK pharmteco (Subsidiary of SK Inc.): Recent Developments and Future Outlook
- Table 12.29 Thermo Fisher Scientific: Company Snapshot
- Table 12.30 Thermo Fisher Scientific: Information on Manufacturing Facilities and Capabilities
- Table 12.31 Thermo Fisher Scientific: Recent Developments and Future Outlook
- Table 13.1 Cell Therapy Manufacturing (Non-Industry Players): List of Organizations Profiled
- Table 13.2 City of Hope: Overview
- Table 13.3 City of Hope: Service Portfolio
- Table 13.4 Clinical Cell and Vaccine Production Facility (CVPF): Overview
- Table 13.5 Clinical Cell and Vaccine Production Facility (CVPF): Service Portfolio
- Table 13.6 Fraunhofer Institute for Cell Therapy and Immunology: Overview
- Table 13.7 Fraunhofer Institute for Cell Therapy and Immunology: Service Portfolio
- Table 13.8 Newcastle Advanced Therapies: Overview
- Table 13.9 Newcastle Advanced Therapies: Service Portfolio
- Table 13.10 NHS Blood and Transplant: Overview
- Table 13.11 NHS Blood and Transplant: Service Portfolio
- Table 13.12 Rayne Cell Therapy Suite (King's College London): Overview
- Table 13.13 Rayne Cell Therapy Suite (King's College London): Service Portfolio
- Table 13.14 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Overview
- Table 13.15 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Service Portfolio
- Table 14.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
- Table 14.2 CellCAN: Overview
- Table 14.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
- Table 14.4 National Cell Manufacturing Consortium: Overview
- Table 14.5 California's Institute of Regenerative Medicine: Overview
- Table 16.1 Cell Therapy Manufacturing: List of Partnerships and Collaborations
- Table 16.2 Partnerships and Collaborations: Information on Type of Immune Cell Offered and Scale of Operation
- Table 16.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
- Table 17.1 Cell Therapy Manufacturing: List of Expansions
- Table 17.2 Cell Therapy Manufacturing: Type of Immune Cell Offered and Scale of Operation
- Table 18.1 List of Top 10 Big Pharma Players
- Table 18.2 Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, Since 2021
- Table 18.3 Big Pharma Initiatives: Information on Type of Immune Cell Offered and Scale of Operation
- Table 19.1 Average Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Sample Data Set for Industry Players
- Table 19.2 Average Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Sample Data Set for Industry Players
- Table 19.3 Global Installed capacity of industry players for cell therapy manufacturing (Number of Cleanrooms): Distribution by Company Size
- Table 19.4 Global Installed capacity of industry players for cell therapy manufacturing (Cleanroom Area): Distribution by Company Size
- Table 19.5 Median Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Data Set for Non-Industry Players
- Table 19.6 Median Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Dat Set for Non-Industry Players
- Table 21.1 Costs Associated with Manufacturing Stem Cell Therapies
- Table 21.2 Pricing Model: Price of Marketed Drugs (Antibody Drug Conjugates and Monoclonal Antibodies)
- Table 21.3 T-cell Immunotherapies: Expert Opinions on Pricing
- Table 21.4 CAR-T Cell Therapies: Reimbursement Landscape
- Table 23.1 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
- Table 23.2 Total Cost of Ownership: Sample Dataset
- Table 25.1 Survey Insights: Overview of Respondents
- Table 25.2 Survey Insights: Designations and Seniority Levels
- Table 25.3 Survey Insights: Type of Cell Therapy
- Table 25.4 Survey Insights: Scale of Operation
- Table 25.5 Survey Insights: Source of Cells
- Table 25.6 Survey Insights: Cell Culture System
- Table 25.7 Survey Insights: Availability of Fill / Finish Services
- Table 39.1 Industry Players: Distribution by Year of Establishment
- Table 39.2 Industry Players: Distribution by Company Size
- Table 39.3 Industry Players: Distribution by Location of Headquarters (Region)
- Table 39.4 Industry Players: Distribution by Location of Headquarters (Country)
- Table 39.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
- Table 39.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
- Table 39.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
- Table 39.8 Industry Players: Distribution by Type of Immune Cell Offered
- Table 39.9 Industry Players: Distribution by Source of Cells
- Table 39.10 Industry Players: Distribution by Scale of Operation
- Table 39.11 Industry Players: Distribution by Type of Additional Service Offered
- Table 39.12 Non-Industry Players: Distribution by Year of Establishment
- Table 39.13 Non-Industry Players: Distribution by Location of Headquarters (Region)
- Table 39.14 Non-Industry Players: Distribution by Location of Headquarters (Country)
- Table 39.15 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
- Table 39.16 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
- Table 39.17 Non-Industry Players: Distribution by Type of Immune Cell Offered
- Table 39.18 Non-Industry Players: Distribution by Source of Cell
- Table 39.19 Non-Industry Players: Distribution by Scale of Operation
- Table 39.20 Non-Industry Players: Distribution by Type of Additional Service Offered
- Table 39.21 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
- Table 39.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
- Table 39.23 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, Since FY 2022 (RMB Billion)
- Table 39.24 AGC Biologics: Annual Revenues, Since FY 2022 (JPY Billion)
- Table 39.25 Catalent: Annual Revenues, Since FY 2021 (USD Billion)
- Table 39.26 Charles River Laboratories: Annual Revenues, Since FY 2022 (USD Billion)
- Table 39.27 ImmunityBio: Annual Revenues, Since FY 2023 (USD Million)
- Table 39.28 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, Since FY 2022 (EUR Billion)
- Table 39.29 Thermo Fisher Scientific: Annual Revenues, Since FY 2022 (JPY Billion)
- Table 39.30 Evotec: Annual Revenues, Since FY 2022 (EUR Million)
- Table 39.31 Lonza: Annual Revenues, Since FY 2022 (CHF Billion)
- Table 39.32 Sartorius: Annual Revenues, Since FY 2022 (EUR Billion)
- Table 39.33 Astellas Pharma: Annual Revenues, Since FY 2022 (YEN Billion)
- Table 39.34 Pharmaron: Annual Revenues, Since FY 2022 (RMB Billion)
- Table 39.35 Takara Bio: Annual Revenues, Since FY 2023 (YEN Billion)
- Table 39.36 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
- Table 39.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
- Table 39.38 Clinical Trial Analysis: Distribution by Trial Status
- Table 39.39 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
- Table 39.40 Clinical Trial Analysis: Distribution by Trial Phase
- Table 39.41 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
- Table 39.42 Clinical Trial Analysis: Distribution by Patient Gender
- Table 39.43 Clinical Trial Analysis: Distribution by Type of Allocation
- Table 39.44 Clinical Trial Analysis: Distribution by Type of Intervention Model
- Table 39.45 Clinical Trial Analysis: Distribution by Type of Masking
- Table 39.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
- Table 39.47 Most Active Industry Players: Distribution by Number of Registered Trials
- Table 39.48 Most Active Non-Industry Players: Distribution by Number of Registered Trials
- Table 39.49 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
- Table 39.50 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
- Table 39.51 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
- Table 39.52 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
- Table 39.53 Partnerships and Collaborations: Distribution by Type of Partnership
- Table 39.54 Partnerships and Collaborations: Distribution by Year and Type of Partnership
- Table 39.55 Partnerships and Collaborations: Distribution by Type of Immune Cell
- Table 39.56 Partnerships and Collaborations: Distribution by Scale of Operation
- Table 39.57 Most Active Players: Distribution by Number of Partnerships
- Table 39.58 Partnerships and Collaborations: Local and International Agreements
- Table 39.59 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
- Table 39.60 Recent Expansions: Cumulative Year-wise Trend, Since 2021
- Table 39.61 Recent Expansions: Distribution by Type of Expansion
- Table 39.62 Recent Expansions: Distribution by Year and Type of Expansion
- Table 39.63 Recent Expansions: Distribution by Location of Expanded Facility (Region)
- Table 39.64 Recent Expansions: Distribution by Location of Expanded Facility (Country)
- Table 39.65 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
- Table 39.66 Recent Expansions: Distribution by Type of Immune Cell
- Table 39.67 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
- Table 39.68 Recent Expansions: Distribution by Scale of Operation
- Table 39.69 Most Active Players: Distribution by Number of Expansions
- Table 39.70 Most Active Players: Distribution by Area of Expansion (in sq. ft)
- Table 39.71 Big Pharma Initiatives: Distribution by Year of Initiative
- Table 39.72 Big Pharma Initiatives: Distribution by Type of Initiative
- Table 39.73 Big Pharma Initiatives: Distribution by Year and Type of Initiative
- Table 39.74 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
- Table 39.75 Big Pharma Initiatives: Distribution by Type of Partnership
- Table 39.76 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
- Table 39.77 Big Pharma Initiatives: Distribution by Type of Facility Expansion
- Table 39.78 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
- Table 39.79 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
- Table 39.80 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
- Table 39.81 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
- Table 39.82 Big Pharma Initiatives: Distribution by Type of Immune Cell
- Table 39.83 Big Pharma Initiatives: Distribution by Scale of Operation
- Table 39.84 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
- Table 39.85 Big Pharma Initiatives Summary
- Table 39.86 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
- Table 39.87 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
- Table 39.88 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
- Table 39.89 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
- Table 39.90 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
- Table 39.91 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
- Table 39.92 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
- Table 39.93 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
- Table 39.94 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
- Table 39.95 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
- Table 39.96 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
- Table 39.97 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
- Table 39.98 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
- Table 39.99 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
- Table 39.100 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
- Table 39.101 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
- Table 39.102 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
- Table 39.103 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
- Table 39.104 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
- Table 39.105 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
- Table 39.106 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Table 39.107 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Table 39.108 Clinical Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Table 39.109 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Table 39.110 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Table 39.111 Commercial Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Table 39.112 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.113 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
- Table 39.114 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
- Table 39.115 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
- Table 39.116 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.117 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.118 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.119 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.120 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.121 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.122 Cell Therapy Manufacturing Market: Distribution by Source of Cells
- Table 39.123 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.124 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.125 Cell Therapy Manufacturing Market: Distribution by Origin of Cells
- Table 39.126 Cell Therapy Manufacturing Market for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.127 Cell Therapy Manufacturing Market for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.128 Cell Therapy Manufacturing Market for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.129 Cell Therapy Manufacturing Market for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.130 Cell Therapy Manufacturing Market for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.131 Cell Therapy Manufacturing Market for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.132 Cell Therapy Manufacturing Market: Distribution by Technology
- Table 39.133 Cell Therapy Manufacturing Market for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.134 Cell Therapy Manufacturing Market for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.135 Cell Therapy Manufacturing Market for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.136 Cell Therapy Manufacturing Market for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.137 Cell Therapy Manufacturing Market for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.138 Cell Therapy Manufacturing Market for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.139 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
- Table 39.140 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.141 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.142 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
- Table 39.143 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.144 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.145 Cell Therapy Manufacturing Market: Distribution by Key Geographical Regions
- Table 39.146 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.147 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.148 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.149 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.150 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.151 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.152 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.153 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.154 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.155 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.156 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.157 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.158 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.159 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.160 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.161 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.162 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.163 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.164 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.165 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.166 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.167 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.168 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.169 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.170 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.171 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.172 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.173 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.174 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.175 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.176 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.177 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.178 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.179 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.180 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Table 39.181 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
List of Figures
- Figure 2.1 Research Methodology: Project Methodology
- Figure 2.2 Research Methodology: Data Sources for Secondary Research
- Figure 2.3 Research Methodology: Robust Quality Control
- Figure 3.1 Market Dynamics: Forecast Methodology
- Figure 3.2 Market Dynamics: Market Assessment Framework
- Figure 4.1 Lessons Learnt from Past Recessions
- Figure 5.1 Executive Summary: Market Landscape
- Figure 5.2 Executive Summary: Market Trends (I / II)
- Figure 5.3 Executive Summary: Market Trends (II / II)
- Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
- Figure 6.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
- Figure 6.2 Decentralized Manufacturing: Process Model
- Figure 6.3 Cell Therapy Manufacturing: Type of Manufacturer
- Figure 6.4 Cell Therapies: Challenges and Drivers
- Figure 6.5 Cell Therapies: Potency as a Critical Quality Attribute
- Figure 6.6 Cell Therapy Manufacturing: Supply Chain Model
- Figure 7.1 Industry Players: Distribution by Year of Establishment
- Figure 7.2 Industry Players: Distribution by Company Size
- Figure 7.3 Industry Players: Distribution by Location of Headquarters (Region)
- Figure 7.4 Industry Players: Distribution by Location of Headquarters (Country)
- Figure 7.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
- Figure 7.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
- Figure 7.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
- Figure 7.8 Industry Players: Distribution by Type of Immune Cell Offered
- Figure 7.9 Industry Players: Distribution by Source of Cells
- Figure 7.10 Industry Players: Distribution by Scale of Operation
- Figure 7.11 Industry Players: Distribution by Type of Additional Service Offered
- Figure 8.1 Non-Industry Players: Distribution by Year of Establishment
- Figure 8.2 Non-Industry Players: Distribution by Location of Headquarters (Region)
- Figure 8.3 Non-Industry Players: Distribution by Location of Headquarters (Country)
- Figure 8.4 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
- Figure 8.5 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
- Figure 8.6 Non-Industry Players: Distribution by Type of Immune Cell Offered
- Figure 8.7 Non-Industry Players: Distribution by Source of Cell
- Figure 8.8 Non-Industry Players: Distribution by Scale of Operation
- Figure 8.9 Non-Industry Players: Distribution by Type of Additional Service Offered
- Figure 9.1 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
- Figure 9.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
- Figure 11.1 Key Considerations for Automating Cell Therapy Manufacturing Process
- Figure 11.2 Requirements to Implement Closed Systems in Cell Therapy Manufacturing Processes
- Figure 11.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
- Figure 11.4 Advantages and Disadvantages of Single-Use System
- Figure 11.5 Growth Drivers and Roadblocks to the Automated and Closed Systems
- Figure 11.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
- Figure 11.7 Cell Therapy Manufacturing: Comparison Between Manual and Automated Processes
- Figure 11.8 Cell Therapy Manufacturing: Comparative Analysis of Manual and Automated Processes Based on Affiliated Costs
- Figure 12.1 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, Since FY 2022 (RMB Billion)
- Figure 12.2 AGC Biologics: Annual Revenues, Since FY 2022 (JPY Billion)
- Figure 12.3 Catalent: Annual Revenues, Since FY 2021 (USD Billion)
- Figure 12.4 Charles River Laboratories: Annual Revenues, Since FY 2022 (USD Billion)
- Figure 12.5 ImmunityBio: Annual Revenues, Since FY 2023 (USD Million)
- Figure 12.6 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, Since FY 2022 (EUR Billion)
- Figure 12.7 Thermo Fisher Scientific: Annual Revenues, Since FY 2022 (JPY Billion)
- Figure 12.8 Evotec: Annual Revenues, Since FY 2022 (EUR Million)
- Figure 12.9 Lonza: Annual Revenues, Since FY 2022 (CHF Billion)
- Figure 12.10 Sartorius: Annual Revenues, Since FY 2022 (EUR Billion)
- Figure 12.11 Astellas Pharma: Annual Revenues, Since FY 2022 (YEN Billion)
- Figure 12.12 Pharmaron: Annual Revenues, Since FY 2022 (RMB Billion)
- Figure 12.13 Takara Bio: Annual Revenues, Since FY 2023 (YEN Billion)
- Figure 13.1 City of Hope: Type of Additional Service Offered
- Figure 13.2 Clinical Cell and Vaccine Production Facility (CVPF): Type of Additional Service Offered
- Figure 13.3 Fraunhofer Institute for Cell Therapy and Immunology: Type of Additional Service Offered
- Figure 13.4 Newcastle Advanced Therapies: Type of Additional Service Offered
- Figure 13.5 NHS Blood and Transplant: Type of Additional Service Offered
- Figure 13.6 Rayne Cell Therapy Suite (King's College London): Type of Additional Service Offered
- Figure 13.7 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Type of Additional Service Offered
- Figure 15.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
- Figure 15.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
- Figure 15.3 Clinical Trial Analysis: Distribution by Trial Status
- Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
- Figure 15.5 Clinical Trial Analysis: Distribution by Trial Phase
- Figure 15.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
- Figure 15.7 Clinical Trial Analysis: Distribution by Patient Gender
- Figure 15.8 Clinical Trial Analysis: Distribution by Type of Allocation
- Figure 15.9 Clinical Trial Analysis: Distribution by Type of Intervention Model
- Figure 15.10 Clinical Trial Analysis: Distribution by Type of Masking
- Figure 15.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
- Figure 15.12 Most Active Industry Players: Distribution by Number of Registered Trials
- Figure 15.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
- Figure 15.14 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
- Figure 15.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
- Figure 15.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
- Figure 16.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
- Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
- Figure 16.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
- Figure 16.4 Partnerships and Collaborations: Distribution by Type of Immune Cell
- Figure 16.5 Partnerships and Collaborations: Distribution by Scale of Operation
- Figure 16.6 Most Active Players: Distribution by Number of Partnerships
- Figure 16.7 Partnerships and Collaborations: Local and International Agreements
- Figure 16.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
- Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, Since 2021
- Figure 17.2 Recent Expansions: Distribution by Type of Expansion
- Figure 17.3 Recent Expansions: Distribution by Year and Type of Expansion
- Figure 17.4 Recent Expansions: Distribution by Location of Expanded Facility (Region)
- Figure 17.5 Recent Expansions: Distribution by Location of Expanded Facility (Country)
- Figure 17.6 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
- Figure 17.7 Recent Expansions: Distribution by Type of Immune Cell
- Figure 17.8 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
- Figure 17.9 Recent Expansions: Distribution by Scale of Operation
- Figure 17.10 Most Active Players: Distribution by Number of Expansions
- Figure 17.11 Most Active Players: Distribution by Area of Expansion (in sq. ft)
- Figure 18.1 Big Pharma Initiatives: Distribution by Year of Initiative
- Figure 18.2 Big Pharma Initiatives: Distribution by Type of Initiative
- Figure 18.3 Big Pharma Initiatives: Distribution by Year and Type of Initiative
- Figure 18.4 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
- Figure 18.5 Big Pharma Initiatives: Distribution by Type of Partnership
- Figure 18.6 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
- Figure 18.7 Big Pharma Initiatives: Distribution by Type of Facility Expansion
- Figure 18.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
- Figure 18.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
- Figure 18.10 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
- Figure 18.11 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
- Figure 18.12 Big Pharma Initiatives: Distribution by Type of Immune Cell
- Figure 18.13 Big Pharma Initiatives: Distribution by Scale of Operation
- Figure 18.14 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
- Figure 18.15 Big Pharma Initiatives Summary
- Figure 19.1 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
- Figure 19.2 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
- Figure 19.3 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
- Figure 19.4 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
- Figure 19.5 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
- Figure 19.6 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
- Figure 19.7 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
- Figure 19.8 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
- Figure 19.9 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
- Figure 19.10 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
- Figure 19.11 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
- Figure 19.12 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
- Figure 19.13 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
- Figure 19.14 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
- Figure 19.15 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
- Figure 19.16 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
- Figure 19.17 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
- Figure 19.18 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
- Figure 20.1 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
- Figure 20.2 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
- Figure 20.3 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Figure 20.4 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Figure 20.5 Clinical Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Figure 20.6 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Figure 20.7 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Figure 20.8 Commercial Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
- Figure 21.1 Targeted Therapies: Pricing Model Based on Patient Segment
- Figure 22.1 Make versus Buy Decision Making Framework
- Figure 22.2 Make versus Buy Decision Making: Possible Scenario Descriptions
- Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
- Figure 23.2 Total Cost of Ownership: Operational Expenditures (OPEX)
- Figure 23.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
- Figure 23.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
- Figure 23.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
- Figure 23.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
- Figure 24.1 Cell Therapy Manufacturing: SWOT Analysis
- Figure 24.2 Comparison of SWOT Factors: Harvey Ball Analysis
- Figure 25.1 Survey Insights: Distribution of Respondents by Type of Organization
- Figure 25.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
- Figure 25.3 Survey Insights: Distribution by Designation and Seniority of Respondents
- Figure 25.4 Survey Insights: Distribution by Type of Cell Therapy
- Figure 25.5 Survey Insights: Distribution by Scale of Operation
- Figure 25.6 Survey Insights: Distribution by Source of Cells
- Figure 25.7 Survey Insights: Distribution by Cell Culture System
- Figure 26.1 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 26.2 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
- Figure 26.3 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
- Figure 27.1 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
- Figure 27.2 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 27.3 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 27.4 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 27.5 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 27.6 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 27.7 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 28.1 Cell Therapy Manufacturing Market: Distribution by Source of Cells
- Figure 28.2 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 28.3 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 29.1 Cell Therapy Manufacturing Market: Distribution by Origin of Cells
- Figure 29.2 Cell Therapy Manufacturing Market for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 29.3 Cell Therapy Manufacturing Market for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 29.4 Cell Therapy Manufacturing Market for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 29.5 Cell Therapy Manufacturing Market for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 29.6 Cell Therapy Manufacturing Market for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 29.7 Cell Therapy Manufacturing Market for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 30.1 Cell Therapy Manufacturing Market: Distribution by Technology
- Figure 30.2 Cell Therapy Manufacturing Market for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 30.3 Cell Therapy Manufacturing Market for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 30.4 Cell Therapy Manufacturing Market for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 30.5 Cell Therapy Manufacturing Market for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 30.6 Cell Therapy Manufacturing Market for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 30.7 Cell Therapy Manufacturing Market for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 31.1 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
- Figure 31.2 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 31.3 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 32.1 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
- Figure 32.2 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 32.3 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.1 Cell Therapy Manufacturing Market: Distribution by Key Geographical Regions
- Figure 33.2 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.3 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.4 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.5 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.6 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.7 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.8 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.9 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.10 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.11 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.12 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.13 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.14 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.15 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.16 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.17 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.18 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.19 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.20 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.21 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.22 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.23 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.24 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.25 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.26 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.27 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.28 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.29 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.30 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.31 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.32 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.33 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.34 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.35 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.36 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 33.37 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
- Figure 37.1 Conclusion: Market Landscape (Industry Players)
- Figure 37.2 Conclusion: Market Landscape (Non-Industry Players)
- Figure 37.3 Conclusion: Clinical Trial Analysis
- Figure 37.4 Conclusion: Partnerships and Collaborations
- Figure 37.5 Conclusion: Recent Expansions
- Figure 37.6 Conclusion: Big Pharma Initiatives
- Figure 37.7 Conclusion: Capacity Analysis
- Figure 37.8 Conclusion: Demand Analysis
- Figure 37.9 Conclusion: Total Cost of Ownership
- Figure 37.10 Conclusion: Market Sizing and Opportunity Analysis
